The Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns

NCT ID: NCT06592430

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-01

Study Completion Date

2026-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The use of smartphone-based WeChat applications offers significant advantages in cancer patient education, rehabilitation monitoring, and postoperative symptom management. Through the WeChat platform, patients can access health education materials, engage in online consultations, and interact with doctors and other patients at any time. This ongoing education and psychological support help alleviate patient anxiety and improve their quality of life. This study aims to conduct a prospective observational study in our hospital to explore the impact of WeChat communication on the prognosis of patients with different histological types and stages of lung cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers

Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers

Intervention Type OTHER

Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers

Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers

Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers

Intervention Type OTHER

Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers

Patients diagnosed with lung cancer use WeChat to communicate with healthcare providers

Intervention Type OTHER

Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers

Patients diagnosed with lung cancer don't use WeChat to communicate with healthcare providers

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) Lung cancer patients receiving treatment at Shanghai Pulmonary Hospital (2) ECOG performance status of 0-2 (3) No other serious internal medical conditions (such as severe heart failure, hypertensive crisis, diabetic ketoacidosis, severe liver or kidney impairment, etc.) (4) No history of other malignant tumors in the past 5 years, and no detection of other tumor history during follow-up after lung cancer diagnosis (5) Relevant pathological results

Exclusion Criteria

* (1) Patients refused enrollment in this study; (2)Patients refused follow-up.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Peng Zhang

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Peng Zhang, PhD

Role: CONTACT

021-65115006

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Wechat-Lung Cancer

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bioinformation Therapy for Lung Cancer
NCT03239171 COMPLETED PHASE2/PHASE3